DMD Advocates Advised HBM Healthcare Investment And Others In ₹850 Cr Pre-IPO Funding Round For OneSource Specialty Pharma

DMD Advocates Advised HBM Healthcare Investment And Others In ₹850 Cr Pre-IPO Funding Round For OneSource Specialty Pharma

DMD Advocates advised HBM Healthcare Investments and other associated investors in leading Onesource’s fundraising of approximately INR 850 crores through a pre-listing round. OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited), a contract development and manufacturing organization (CDMO) platform, is an associate of Strides Pharma and its shares are to be listed shortly.

The capital raised will support Onesource’s growth, advance its research and development, and enhance its product offerings, which will strengthen the company’s market position ahead of its IPO.

The transaction at DMD Advocates was led by Partner Ayesha Rai, along with Principal Associate Pooja Shah and Associate Vanshikha Choraria. Lead Partner Vihang Virkar acted as the engagement Partner for this assignment.